RESUMEN
Amongst a wide range of biological macromolecules, saccharides exhibit the potential to be specifically recognized by cell-surface receptors and hence can be utilized as ligands in targeted drug delivery. The current study aims to use saccharides viz. Galactose, Pectin and Chitosan to improve targeting of Atenolol by oxalyl chloride mediated grafting. Conjugates were engineered by grafting Atenolol, a cardiovascular agent with the modified saccharide units. The conjugates were characterized by FTIR, DSC and 1H NMR study. Drug release analysis and cellular uptake study was carried out using H9c2 cell lines which represent that concentration of drug in cells treated with all atenolol-saccharide conjugates is enhanced by almost two-folds in comparison with cells treated with atenolol solution. Thus cell line study confers the evidence of selective cardiac delivery. No significant cytotoxicity was observed in case of all synthesized conjugates in the Brine shrimp lethality bioassay. Possible binding of the developed conjugates with the GLUT-4 receptors was assessed by in silico analysis using homology model developed by Swiss Model server. Hence it was concluded that the application of these conjugates with saccharides in selective cardiovascular drug delivery can be a promising approach to increase bioavailability, minimize drug loss by degradation and prevent harmful side effects by increasing specific cell targeting.
Asunto(s)
Atenolol/química , Atenolol/farmacología , Portadores de Fármacos/química , Antagonistas de Receptores Adrenérgicos beta 1/química , Antagonistas de Receptores Adrenérgicos beta 1/farmacología , Animales , Artemia/efectos de los fármacos , Atenolol/metabolismo , Atenolol/toxicidad , Línea Celular , Quitosano/química , Simulación por Computador , Portadores de Fármacos/farmacología , Portadores de Fármacos/toxicidad , Evaluación Preclínica de Medicamentos , Galactosa/química , Transportador de Glucosa de Tipo 4/química , Transportador de Glucosa de Tipo 4/metabolismo , Dosificación Letal Mediana , Espectroscopía de Resonancia Magnética , Miocardio/citología , Pectinas/química , Ratas , Espectroscopía Infrarroja por Transformada de FourierRESUMEN
RATIONAL & OBJECTIVE: Beta-blockers are recommended for patients with heart failure (HF) but their benefit in the dialysis population is uncertain. Beta-blockers are heterogeneous, including with respect to their removal by hemodialysis. We sought to evaluate whether ß-blocker use and their dialyzability characteristics were associated with early mortality among patients with chronic kidney disease with HF who transitioned to dialysis. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Adults patients with chronic kidney disease (aged≥18 years) and HF who initiated either hemodialysis or peritoneal dialysis during January 1, 2007, to June 30, 2016, within an integrated health system were included. EXPOSURES: Patients were considered treated with ß-blockers if they had a quantity of drug dispensed covering the dialysis transition date. OUTCOMES: All-cause mortality within 6 months and 1 year or hospitalization within 6 months after transition to maintenance dialysis. ANALYTICAL APPROACH: Inverse probability of treatment weights using propensity scores was used to balance covariates between treatment groups. Cox proportional hazard analysis and logistic regression were used to investigate the association between ß-blocker use and study outcomes. RESULTS: 3,503 patients were included in the study. There were 2,115 (60.4%) patients using ß-blockers at transition. Compared with nonusers, the HR for all-cause mortality within 6 months was 0.79 (95% CI, 0.65-0.94) among users of any ß-blocker and 0.68 (95% CI, 0.53-0.88) among users of metoprolol at transition. There were no observed differences in all-cause or cardiovascular-related hospitalization. LIMITATIONS: The observational nature of our study could not fully account for residual confounding. CONCLUSIONS: Beta-blockers were associated with a lower rate of mortality among incident hemodialysis patients with HF. Similar associations were not observed for hospitalizations within the first 6 months following transition to dialysis.
Asunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológico , Hospitalización/estadística & datos numéricos , Fallo Renal Crónico/terapia , Mortalidad , Diálisis Renal , Antagonistas Adrenérgicos beta/metabolismo , Anciano , Anciano de 80 o más Años , Atenolol/metabolismo , Atenolol/uso terapéutico , Bisoprolol/metabolismo , Bisoprolol/uso terapéutico , Carvedilol/metabolismo , Carvedilol/uso terapéutico , Causas de Muerte , Estudios de Cohortes , Femenino , Insuficiencia Cardíaca/complicaciones , Humanos , Fallo Renal Crónico/complicaciones , Labetalol/metabolismo , Labetalol/uso terapéutico , Modelos Logísticos , Masculino , Metoprolol/metabolismo , Metoprolol/uso terapéutico , Persona de Mediana Edad , Nadolol/metabolismo , Nadolol/uso terapéutico , Modelos de Riesgos Proporcionales , Propranolol/metabolismo , Propranolol/uso terapéutico , Factores Protectores , Estudios Retrospectivos , Riesgo , Factores de RiesgoRESUMEN
Tongmai formula (TMF) is a well-known Chinese medicinal preparation that contains isoflavones as its major bioactive constituents. As traditional Chinese medicines (TCMs) are usually used by oral administration, their fate inside the intestinal lumen, including their biotransformation by human intestinal flora (HIF) and intestinal absorption deserves study. In this work TMF extract was incubated with human intestinal bacteria under anaerobic conditions and the changes in the twelve main constituents of TMF were then investigated. Their intestinal permeabilities, i.e., the transport capability across the intestinal brush border were investigated with a human colon carcinoma cell line (Caco-2) cell monolayer model to predict the absorption mechanism. Meanwhile, rapid HPLC-DAD methods were established for the assay. According to the biotransformation curves of the twelve constituents and the permeability coefficients, the intestinal absorption capacity of the typical compounds was elevated from the levels of 10(-7) cm/s to 10(-5) cm/s from those of the original compounds in TMF. Among them the main isoflavone glycosides puerarin (4), mirificin (6) and daidzin (7) were transformed into the same aglycone, daidzein (10). Therefore it was predicted that the aglycone compounds might be the real active ingredients in TMF. The models used can represent a novel path for the TCM studies.
Asunto(s)
Bacterias/metabolismo , Medicamentos Herbarios Chinos/metabolismo , Microbioma Gastrointestinal/fisiología , Isoflavonas/biosíntesis , Consorcios Microbianos/fisiología , Atenolol/metabolismo , Transporte Biológico , Biotransformación , Células CACO-2 , Enfermedades Cardiovasculares/tratamiento farmacológico , Medicamentos Herbarios Chinos/química , Medicamentos Herbarios Chinos/farmacología , Heces/microbiología , Humanos , Isoflavonas/aislamiento & purificación , Isoflavonas/metabolismo , Medicina Tradicional China , Permeabilidad , Propranolol/metabolismoRESUMEN
Pharmaceutically active compounds (PACs) are continuously dispersed into the environment due to human and veterinary use, giving rise to their potential accumulation in edible plants. In this study, Eruca sativa L. and Zea mays L. were selected to determine the potential uptake and accumulation of eight different PACs (Salbutamol, Atenolol, Lincomycin, Cyclophosphamide, Carbamazepine, Bezafibrate, Ofloxacin and Ranitidine) designed for human use. To mimic environmental conditions, the plants were grown in pots and irrigated with water spiked with a mixture of PACs at concentrations found in Italian wastewaters and rivers. Moreover, 10× and 100× concentrations of these pharmaceuticals were also tested. The presence of the pharmaceuticals was tested in the edible parts of the plants, namely leaves for E. sativa and grains for Z. mays. Quantification was performed by liquid chromatography mass spectroscopy (LC/MS/MS). In the grains of 100× treated Z. mays, only atenolol, lincomycin and carbamazepine were above the limit of detection (LOD). At the same concentration in E. sativa plants the uptake of all PACs was >LOD. Lincomycin and oflaxacin were above the limit of quantitation in all conditions tested in E. sativa. The results suggest that uptake of some pharmaceuticals from the soil may indeed be a potential transport route to plants and that these environmental pollutants can reach different edible parts of the selected crops. Measurements of the concentrations of these pharmaceuticals in plant materials were used to model potential adult human exposure to these compounds. The results indicate that under the current experimental conditions, crops exposed to the selected pharmaceutical mixture would not have any negative effects on human health. Moreover, no significant differences in the growth of E. sativa or Z. mays plants irrigated with PAC-spiked vs. non-spiked water were observed.
Asunto(s)
Brassicaceae/metabolismo , Preparaciones Farmacéuticas/metabolismo , Contaminantes Químicos del Agua/metabolismo , Zea mays/metabolismo , Albuterol/metabolismo , Albuterol/toxicidad , Atenolol/metabolismo , Atenolol/toxicidad , Bezafibrato/metabolismo , Bezafibrato/toxicidad , Brassicaceae/efectos de los fármacos , Brassicaceae/crecimiento & desarrollo , Carbamazepina/metabolismo , Carbamazepina/toxicidad , Ciclofosfamida/metabolismo , Ciclofosfamida/toxicidad , Interacciones Farmacológicas , Germinación/efectos de los fármacos , Humanos , Lincomicina/metabolismo , Lincomicina/toxicidad , Ofloxacino/metabolismo , Ofloxacino/toxicidad , Ranitidina/metabolismo , Ranitidina/toxicidad , Ríos , Espectrometría de Masas en Tándem , Aguas Residuales , Contaminantes Químicos del Agua/toxicidad , Zea mays/efectos de los fármacos , Zea mays/crecimiento & desarrolloRESUMEN
Aloe vera gel previously showed the ability to increase the bioavailability of vitamins and to enhance the in vitro transport of a macromolecular drug across intestinal epithelial cell monolayers. The purpose of this study is to investigate the potential of other species of aloe to act as drug absorption enhancement agents. The effect of gel materials from three South African aloes; Aloe ferox, A. marlothii and A. speciosa on the transepithelial electrical resistance and permeability of atenolol across excised intestinal tissue of the rat as well as the transport of FITC-dextran across Caco-2 cell monolayers was investigated. The aloe gel materials exhibited the ability to statistically significantly reduce the transepithelial electrical resistance of excised rat intestinal tissue but did not significantly increase the transport of atenolol across this in vitro tissue model at the concentrations tested. At least one concentration of each aloe gel material enhanced the transport of FITC-dextran statistically significantly across Caco-2 cell monolayers. The aloe gel materials showed potential to act as drug absorption enhancing agents across intestinal epithelia. The absorption enhancement effect was dependent on the type of in vitro model and type of drug was investigated.
Asunto(s)
Aloe , Absorción Intestinal/efectos de los fármacos , Yeyuno/metabolismo , Preparaciones de Plantas/farmacología , Animales , Atenolol/metabolismo , Células CACO-2 , Dextranos/metabolismo , Fluoresceína-5-Isotiocianato/análogos & derivados , Fluoresceína-5-Isotiocianato/metabolismo , Geles , Humanos , Técnicas In Vitro , Permeabilidad , Hojas de la Planta , Ratas , Ratas Sprague-DawleyRESUMEN
Human CYP3A4, the major human, intestinal, drug metabolizing cytochrome P450, has been introduced into three mammalian cell lines (Caco-2, MDCK and LLC-PK1) suitable for making drug permeability measurements. The levels and stability of expression were analyzed by enzyme assays (testosterone 6beta-hydroxylase and nifedipine oxidase). Long term, stable CYP3A4 expression/cell growth rate was obtained in MDCK cells. In the LLC-PK1 system, shorter term, stable expression was achieved. However, in Caco-2 cells, derivatives with better properties than those previously reported could not be obtained. The highest level of CYP3A4 catalytic activity was obtained in LLC-PK1 cells. In this system, CYP3A4 activity levels appeared comparable to median level human intestinal microsomes. Metabolite formation and inhibition kinetics were examined in cell monolayers. Nifedipine was found to be extensively metabolized (19%) during passage across cell monolayers. In general, affinity related parameters (apparent Km and apparent Ki) were 1.5- to three-fold higher under conditions of flux through the monolayers relative to steady-state conditions. These systems should be useful for examining the role of intestinal CYP3A4 in first-pass metabolism and drug-drug interactions.